Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-0509
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model ; volume:11 ; number:1 ; day:19 ; month:7 ; year:2017 ; pages:1-18 ; date:12.2017
BMC systems biology ; 11, Heft 1 (19.7.2017), 1-18, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Lai, Xiulan
- Contributor
-
Friedman, Avner
SpringerLink (Online service)
- DOI
-
10.1186/s12918-017-0446-9
- URN
-
urn:nbn:de:1111-201710245678
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lai, Xiulan
- Friedman, Avner
- SpringerLink (Online service)
Other Objects (12)
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Zielgerichtete Kombinationstherapie von BRAF- und MEK-Inhibitor resistenten Melanomzellen
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Efficacy of the MEK inhibitor trametinib in combination with disulfiram in BRAF-wild type melanoma cells